Results 171 to 180 of about 70,554 (222)

Pharmacist-Led Prevention of Recurrent Cetuximab Infusion Reactions. [PDF]

Cureus
Yamada Y, Fukuyama A, Miyazaki M, Sumi Y, Fukue H, Nakashima A, Akasaki T, Imakyure O.   +7 more
europepmc   +1 more source

Chelation-Controlled Oriented and Irreversible Immobilization of Native Antibodies on Photoreactive Magnetic Nanoparticles. [PDF]

ACS Appl Bio Mater
Huo YR, Adak AK, Kawade SK, Chen YJ, Dela Rosa MAC, Chen YJ, Lin CC.   +6 more
europepmc   +1 more source

Antisense oligonucleotide targeting TARDBP-EGFR splicing axis inhibits progression of oral squamous cell carcinoma through ABCA1-regulated cholesterol efflux. [PDF]

Int J Oral Sci
Ni N, Wang M, Yuan Z, Zhang L, Cai J, Du Q, Li P, Gao C, Zhang H, Li Y, Yuan H.   +10 more
europepmc   +1 more source

Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway. [PDF]

J Immunother Cancer
Beers C, Ilaria RL, Luke JJ.
europepmc   +1 more source

Emerging and Investigational Systemic Therapies in Recurrent/Metastatic Head and Neck Cancer After Progression on Immunotherapy. [PDF]

Cancers (Basel)
Abraham FF, Julian R.
europepmc   +1 more source

Closing the loop on EGFR therapy: decoding cetuximab response through circ-EGFR. [PDF]

EMBO Mol Med
Pilati C, Laurent-Puig P.
europepmc   +1 more source

Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: A systematic review [PDF]

, 2018
Anadkat, Milan, Bohac, Chet, Garawin, Tamer, Jatoi, Aminah, Lacouture, Mario E, Mitchell, Edith   +5 more
core   +1 more source

Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy. [PDF]

Cell Rep Med
Chiu PH, Lai KC, Wang HL, Chang YW, Wu WC, Chen TH, Tsai YS, Song JH, Sun NY, Chau GY, Fang WL, Chen JP, Wang HM, Huang HC, Hsieh MC, Hua CH, Lien MY, Chang YF, Wang HC, Chien CY, Huang TL, Wang CC, Liu YC, Chen JP, Lu WC, Yiu CY, Lin CL, Lou PJ, Chu PY, Wang SC, Hung MC, Yang MH.   +31 more
europepmc   +1 more source

Comparative effectiveness of bevacizumab, cetuximab, and panitumumab for improving outcomes in metastatic colorectal cancer: a propensity overlap weighting analysis. [PDF]

Ann Coloproctol
Su YC, Su CC, Lee PT, Wu CC.
europepmc   +1 more source

A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors. [PDF]

Nat Commun
da Silva Bortoleti BT, Quasem S, Maurer S, Zhong X, Pimenta R, Ribeiro de Lima Brandão L, Hernandez M, Fraidenburg M, Alves da Silva PH, Alvarez R, Chen BK, Diniz MA, Housman B, Flores RM, Brody R, Marron TU, Ferrari de Andrade L.   +16 more
europepmc   +1 more source